Ambitious plans for leading cancer research centre announced
Ella Day | May 2, 2025 | News story | Market & Product Development, Medical Communications, Research and Development | Aviva Capital Partners (ACP), Institute of Cancer Research (ICR), London, London Cancer Hub, Oncology, Royal Marsden NHS Foundation Trust, Socius
Aviva Capital Partners (ACP), an infrastructure and real estate investor, and Socius, a mixed-use developer, have unveiled plans for a new £1bn project to create a globally leading centre for cancer research and treatment in Sutton, London. It intends to bring leading life sciences researchers and organisations together to drive innovation in cancer research.
Spanning 12 acres, the site will join the London Cancer Hub next to leading cancer institutions, the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust’s Sutton site, a prominent cancer treatment centre.
“Our plans foster better connectivity between the buildings, more natural collision points and places to meet to drive collaboration and innovation,” said Barry Jessup, managing director of Socius.
The London Borough of Sutton anticipates that the site will contribute significantly to London’s growth, estimated to bring £1.2bn annually to the UK economy and support 13,000 jobs.
Operations aim to achieve net-zero carbon emissions, exceeding mandatory sustainability and energy efficient standards. The hub will include a diversity of facilities including large-scale facilities for global companies, as well as smaller labs for start-ups.
CEO of the ICR, Kristian Helin, commented: “The London Cancer Hub has great potential to enhance our scientific partnerships with companies in the pharmaceutical and broader life-sciences industries.”
“We anticipate this development will facilitate greater collaboration and foster an environment of excellence to further our work developing new and improved ways to diagnose, treat and care for our patients,” added Dame Cally Palmer, CEO of The Royal Marsden NHS Foundation Trust.
Ella Day
2/5/25
Related Content
Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London
Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …
MSD unveils plans for $1.3bn central London research centre
MSD has lifted the lid on plans to build a $1.3 billion research centre in …
London’s water contains high levels of antibiotic-resistant genes, UCL research reveals
Research from University College London has warned that freshwater sources in the English capital of …
